Daiichi Sankyo, Inc., of Parsippany, N.J., the U.S. subsidiary of Japan’s second-largest pharmaceutical company, has received approval for Azor (amlodipine and olmesartan medoxomil), a once-daily single tablet for the treatment of hypertension.


The combination of the calcium channel blocker amlodipine with olmesartan medoxomil, the active ingredient in Daiichi Sankyo’s flagship angiotensin receptor blocker (Benicar), will give doctors a convenient new treatment option for hypertensive patients who need to reduce their BP levels or who are uncontrolled on other therapies.

Continue Reading


When compared in clinical trials to amlodipine 10 mg alone, Azor 10/40 mg significantly reduced mean diastolic and mean systolic BP.


“Azor with its established efficacy and favorable side effect profile provides two complementary mechanisms of action to lower blood pressure,” stated Michael A. Weber, MD, professor of medicine, State University of New York Downstate College of Medicine in Brooklyn.